Abstract: Sinotau, a China-based radiopharmaceutical company with three marketed products, is seeking a Hong Kong listing under the biotech rules. GF, CICC and CITIC are the joint sponsors. In our previous note, we looked at the company's core products XTR008, XTR006, XTR004 and XTR003, as well as its management and investor backing. In this note, we look at the developments in the company's assets and the competitive position of each product.
HENGRUI PHARMA, Lantheus, NOVN SW, GRAND PHARMA, GE HealthCare Technologies Inc. Common Stock
Research on Hong Kong and A+H equity offerings, from the first filing to the aftermarket. Coverage includes pre-IPO early thoughts on the business and valuation, analysis of the final deal terms and cornerstone investors, and updates as new prospectus versions are filed.
Interested in the full report? Get in touch with our team.
We will review your request. Once approved, the report will be sent to your company email.
Thank you! We will review your request and email the report to you, usually within 1 business day.